Non-alcoholic fatty liver disease (NAFLD) is a highly prevalent, progressive disorder and growing public health concern. To date, no treatments exist for NAFLD. To address this issue, considerable research has been undertaken in pursuit of new NAFLD therapeutics. Development of effective, high-throughput in vitro models are an important aspect of drug discovery. Here, a micropatterned hepatocyte coculture (MPCC) was used to model liver steatosis and NAFLD. The MPCC model (HEPATOPAC) involves cells patterned onto a standard 96-well plate, increasing throughput and allowing the cultures can be handled and imaged like 2D cultures. Treatment of MPCC with free fatty acids (FFA), high glucose and fructose (HGF), or a combination of both induces hepatic steatosis. Additionally, inclusion of Kupffer cells to generate a tri-culture (MPTC) increased lipid loading induced by steatotic media. MPCC treatment with ACC1/ACC2 inhibitors, as either a preventative or reversal agent showed efficacy against FFA induced hepatic steatosis. Drug induced steatosis was also evaluated. Treatment with valproic acid showed steatosis induction in a lean background, which was significantly potentiated in a fatty liver background. Additionally, these media treatments changed expression of fatty liver related genes. Treatment of MPCC with FFA, HGF, or a combination reversibly altered expression of genes involved in fatty acid metabolism, insulin signaling, and lipid transport. These changes were largely consistent with data from other clinical or in vivo fatty liver studies. Together, these data demonstrate that MPCC and MPTC are easy to use long-term functional in vitro models of NAFLD. MPCC and MPTC are able to replicate numerous clinical and in vivo NAFLD observations, allowing their broad utility for compound screening, drug toxicity evaluation and assessment of gene expression changes.